# OnCo record nicoletta-colombo (person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/people/nicoletta-colombo/>
  a schema:Person ;
  onco:kind "person" ;
  schema:identifier "nicoletta-colombo" ;
  schema:name "Nicoletta Colombo"@en ;
  schema:description "Led KEYNOTE-826, which made pembrolizumab plus chemotherapy the first-line standard for recurrent or metastatic cervical cancer."@en ;
  schema:url <https://onco.cc/people/nicoletta-colombo/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=Colombo%20N%5BAuthor%5D%20cervical%20pembrolizumab> ;
  onco:tag "cervical", "immunotherapy", "guidelines" ;
  schema:jobTitle "Director of Gynaecologic Oncology, European Institute of Oncology (IEO), Milan; Professor, University of Milan-Bicocca" ;
  onco:cancers <https://onco.cc/cancers/cervical/>, <https://onco.cc/cancers/ovarian/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/vegf/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:institutions <https://onco.cc/institutions/ieo-milan/>, <https://onco.cc/institutions/esgo/> ;
  onco:trials <https://onco.cc/trials/keynote-826/> ;
  schema:affiliation <https://onco.cc/institutions/ieo-milan/> .